CEO Haruo Naito highlighted a 9% year-on-year revenue increase to 601.2 billion yen, with a focus on the pharmaceutical business driving growth. Key contributors included LEQEMBI with a 28.1 billion ...

The EC requests CHMP to reassess new safety data that emerged after the positive opinion recommending the approval of ...

BioArctic’s partner Eisai announces update on regulatory review of lecanemab to treat early Alzheimer’s disease in EU: Stockholm Monday, February 3, 2025, 13:00 Hrs [IST] BioA ...

The Washington University trial comes as part of a larger platform study which hopes to understand if Alzheimer's disease can ...

Japan’s Eisai and US partner Biogen have announced today update on the ongoing regulatory review of the Marketing Authorization Application for lecanemab (trade name Leqembi) as a treatment for early ...

MRK posts encouraging Q4 results. However, the decision to temporarily halt shipments of Gardasil vaccines to China has ...

With the overall stock market very overbought, the four highest-yielding Dogs of the Dow look like outstanding ideas now.

In Japan, Eisai and Biogen Japan will co-promote Leqembi, with Eisai distributing the product as the marketing authorisation holder (MAH). In the US – where the drug was granted accelerated ...

Welcome to the Merck & Company Q4 sales and earnings conference call. [Operator instructions] This call is being recorded.

Learn more about whether Biogen Inc. or Neurocrine Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Eisai and Biogen have moved swiftly ahead with ... and Wales will depend upon approval by the Medicines and Healthcare products Regulatory Agency (MHRA) – the Alzheimer's Society has called ...